No Data
No Data
Catalyst Watch: HP Enterprise Event, Walmart+ Week, Pure Storage Buzz, and Triple-witching Volatility
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Keros Therapeutics(KROS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.9% and a total average return o
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
LEXINGTON, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercial
Express News | Keros Therapeutics Appoints Jean-Jacques Bienaimé to Its Board of Directors
Keros Therapeutics Reports Widening Losses in Q1 2024, Despite Progress in Clinical Trials
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Keros Therapeutics (KROS)